David L. Grange - May 8, 2023 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Director
Signature
/s/ Jessica Morris, Attorney-in-Fact
Stock symbol
TNXP
Transactions as of
May 8, 2023
Transactions value $
$0
Form type
4
Date filed
5/10/2023, 05:13 PM
Previous filing
May 11, 2022
Next filing
May 24, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +60K $0.00 60K May 8, 2023 Common Stock 60K $0.51 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2024 Annual Meeting of Stockholders.
F2 Does not reflect a 1-for-6.25 reverse stock split of the Issuer's common stock effective May 10, 2023.